AKBA
Akebia Therapeutics, Inc.
0.8734$
-0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -3,924.8% | – | 3,772.4% | -31.6% | -46.9% | -76.8% | -37.4% | -118.4% | -25.0% | -12.0% | -25.4% | 28.8% | |
| – | – | 7.0% | – | 19.3% | 0.3% | 1.2% | 11.5% | 11.4% | 17.8% | 12.9% | 19.3% | 23.4% | 0.5% | |
| – | – | 858.3% | – | 379.5% | 5.0% | 9.2% | 3.6% | 8.3% | 10.6% | 6.1% | 4.8% | 4.9% | 4.8% | |
| – | – | 858.3% | – | 399.4% | 6.9% | 2.0% | 4.6% | 54.1% | 17.4% | 16.0% | – | – | – | |
| – | – | 460.4% | – | 12,165.0% | 4.1% | 17.3% | -29.6% | -4.6% | -49.4% | -0.5% | -10.6% | -24.8% | 7.0% | |
| – | – | 32.7% | – | 173.4% | 0.9% | 0.8% | 2.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | |
| – | – | -9,332.9% | – | 827.7% | -99.6% | 17.6% | 63.0% | -13.5% | 18.7% | 0.0% | – | 0.0% | -3.4% | |
| – | – | 0.0% | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | -23.1% | – | 4,362.6% | 65.3% | 46.5% | -0.1% | 71.7% | 41.6% | 2.6% | 0.0% | -0.8% | – | |
| – | – | 33.4% | – | -1.3% | 0.0% | 0.0% | 18.7% | 6.8% | -15.5% | -11.3% | -16.4% | 4.9% | 4.0% | |
| – | – | 14,909.3% | – | 4,361.3% | 65.3% | 46.5% | 26.6% | 78.5% | 62.6% | 5.0% | -13.0% | 31.0% | 30.9% | |
| – | – | 1,651.6% | – | 8,961.4% | -65.8% | 17.2% | 12.7% | 27.5% | -37.1% | -20.1% | -25.0% | 5.6% | 56.3% | |
| – | – | -3,957.5% | – | 3,599.0% | -32.5% | -47.7% | -78.8% | -37.5% | -118.5% | -25.1% | -12.0% | -25.4% | 28.8% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.